Comprehensive panels for hereditary cancer    

Revealing a detailed picture

For cancer patients and individuals with a family history of multiple cancers, in-depth genetic testing can determine whether the cancer is hereditary in origin. Our comprehensive hereditary cancer panels use next generation sequencing to evaluate dozens of genes for personalized insights into whether an individual carries a heritable, elevated risk for cancer. Patients identified with a hereditary cancer syndrome can benefit from directed treatment choices, personalized surveillance, and understanding of their cancer risks.

Which test should I order?

XCP | Hereditary Expanded Panel

  • Assesses 87 genes associated with an increased risk of a variety of cancers, including breast cancer, colon cancer, gastric cancer, paragangliomas, pheochromocytomas, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, skin cancer, thyroid cancer, endometrial cancer, and Wilms tumor
  • Helps identify patients with common and rare hereditary cancer syndromes when the patient has a variety of cancers in their personal or family history

COMCP  | Hereditary Common Cancer Panel

  • Assesses 36 genes associated with an increased risk for common cancers, including breast, colon, gastric, ovarian, pancreatic, prostate, skin, thyroid, endometrial, and polyposis
  • Helps identify patients with common hereditary cancer syndromes when the patient has multiple cancers in their personal or family history

Test in focus

Wei Shen, Ph.D., explains Mayo Clinic Laboratories' new expert-backed, hereditary oncology panels, which use next-generation sequencing to identify genetic mutations linked to increased cancer risk. By only including clinically significant genes, the panels provide clarity on diagnosis, prognosis, and treatment approaches.

Learn more about how to order these tests at your institution.